Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cabaletta Bio, Inc. (CABA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.58, with a market capitalisation of $493.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.90 to $4.23. This page covers its latest market performance, valuation, price trends and company information.
$493.38M | |
$2.63 | |
$26.35 | |
$0.59 | |
$2.60 | |
2.41K | |
5.11M | |
-- | |
$4.23 | |
$1.90 | |
-- | |
-- |
Cabaletta Bio, Inc. (CABA) is trading at $2.58 in pre-market trading as of 2026-09-16 10:28:00, down 0.58% ($0.02) from the previous close of $2.60
Pre-market trading shows how investors are pricing CABA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Cabaletta Bio, Inc. (CABA) moved from $3.47 to $2.58, representing a decline of 25.65% ($0.89).
The stock traded between $2.57 and $3.60 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 6.08 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.0%
CABA is currently trading at $2.58, placing it 29.0% of the way from its 52-week low of $1.90 to its 52-week high of $4.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 158 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cabaletta Bio, Inc. (CABA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.